EFFICACY AND TOLERABILITY OF ORAL IRON CHELATOR, DEFERASIROX

Authors

  • Awais Tahir Children Department,Fauji Foundation Hospital, Rawalpindi
  • Syed Ibrar Hussain Children department, Fauji foundation Hospital, Rawalpindi-Pakistan
  • Huma Saleem Khan Children Department,Fauji Foundation Hospital, Rawalpindi
  • Sumaira Khalil Children Department,Fauji Foundation Hospital, Rawalpindi
  • Syed Zulfiqar Haider Children Department,Fauji Foundation Hospital, Rawalpindi
  • Munir Akmal Lodhi Children Department,Fauji Foundation Hospital, Rawalpindi

Abstract

Background: Thalassemia major is the severe form of β thalassemia characterized by severe anaemia, hepatosplenomegaly and facioskeletal changes due to increased haemolysis of defective red blood cells. In iron overload states, high levels of iron exceed the iron-carrying capacity of transferrin within the plasma, leading to the formation of nontransferrin-bound iron form. These nontransferrin-bound iron forms can be taken up into cells, including liver, heart, and endocrine cells leading to organ damage. To prevent complications associated with hemosiderosis, iron chelation therapy remains one of the main objectives of clinical management of the patients affected by Thalassemia Major. Methods: Thirty-seven patients were enrolled using non randomized convenience sampling technique after the written consent from patients. Patients age 2–30 years were enrolled in this study. Serum Ferritin, ALT, Serum Creatinine were checked at the start of the study, 3 months, 6months and then at the end of the study, i.e., at 9 months of the commencement of the study. They were also assessed for other side effects pertaining to oral tolerability of the drug like vomiting, nausea, GI upset, diarrhoea, urinary complaints or any other subjective complaint. Results: Of the 37 patients, 20 were male (54.1%) and 17 were female (45.9%). Mean age of the patients was 10.2 years (Min. 3 years, Max 21 years). The average serum Ferritin at baseline was noted as 3440 which increased after a period of 3 months, 6 months and 9 months with average of 3359, 3677 and 4394 respectively. After the period of 9 months largest 95% confidence interval of serum Ferritin levels was observed in the range of 3420.17 to 5368.63. In our study, 17 patients required alternative chelation (46%). These patients needed IV Deferioxamine because of the rising trend of Serum Ferritin after the study. Conclusion: From the results of our study, we infer that oral Deferasirox is not an effective iron chelator. If the patients are taking oral deferasirox, their Serum Ferritin should be checked 3 monthlies. The drug is effective only in maintaining Serum Ferritin levels with levels less than 1500ng/ml. Intravenous Deferioxamine still should be preferred over oral iron chelators for effective control of iron overload and its complications. 

Author Biography

Awais Tahir, Children Department,Fauji Foundation Hospital, Rawalpindi

Assistant professor and classified child specialist

References

Benz EJ. Hemoglobinopathies. In: Longo D, Kasper D, Jameson J, Fauci A, Hauser S, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 18th ed. New York: McGraw-Hill, 2012; p.698–702.

Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86:480–7.

Thakor DR, Desai CK, Kapadia JD, Dikshit RK, Mehariya KM. Efficacy and safety of deferasirox in pediatric patients of thalassemia at a Tertiary Care Teaching Hospital. Indian J Med Pediatr Oncol 2017;38(2):103–10.

Hassan MA, Tolba OA. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electron Physician 2016;8(5):2425–31.

Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2009;148(3):466–75.

Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127(3):348–55.

Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331(9):567–73.

Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB, et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos 1993;21(4):640–4.

Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003;43(6):565–72.

Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol 2008;48(4):428–35.

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107(9):3455–462.

Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010;115(12):2364–71.

Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, et al. Chelation choices and iron burden among patients with thalassemia in the 21st century: a report from the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort. Blood 2009;114(22):4056.

Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29(5):909–17.

Ware HM, Kwiatkowski JL. Optimal Use of Iron Chelators in Pediatric Patients. Clin Adv Hematol Oncol 2013;11(7):433–41.

Ejaz MS, Baloch S, Arif F. Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major. Pak J Med Sci 2015;31(3):621–5.

Aycicek A, Koc A, Abuhandan M. Efficacy of deferasirox in children with β-thalassemia: single-center 3 years experience. Pediatr Int 2014;56(4):530–3.

Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis 2011;47(3):166–75.

Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, et al. Follow-up report on the 2-year cardiac data from a deferasiroxmonotherapy trial. Am J Hematol 2010;85(10):818–9.

Karami H, Kosaryan M, Amree AH, Darvishi-Khezri H, Mousavi M. Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major. Clin Pract 2017;7(1):912.

Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelatorsdeferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol 2015;95(5):411–20.

Taher AT, Cappellini MD, Aydinok Y, Porter JB, Karakas Z, Viprakasit V, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells Mol Dis 2016;57:23–9.

Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011;154(3):387–97.

Bruch HR, Dencausse Y, Heßling J, Michl G, Schlag R, Skorupa A, et al. CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload. Oncol Res Treat 2016;39(7-8):424–31.

Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009;82(6):458–65.

Grangé S, Bertrand DM, Guerrot D, Eas F, Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant 2010;25(7):2376–8.

Sánchez-González PD, López-Hernandez FJ, Morales AI, Macías-Nuñez JF, López-Novoa JM. Effects of deferasirox on renal function and renal epithelial cell death. Toxicol Lett 2011;203(2):154–61.

Dubourg L, Laurain C, Ranchin B, Pondarré C, Hadj-Aïssa A, Sigaudo-Roussel D, et al. Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Pediatr Nephrol 2012;27(11):2115–22.

Published

2021-04-23